dMMR
4 drugsPredictive biomarker for patient selection in 31 indications
4
Approved Drugs
31
Indications
2
Companies
dMMR is a precision-medicine biomarker linked to 4 FDA-approved targeted drugs from 2 companies, spanning 31 indications including Renal Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer. Explore the targeted therapies, indications, testing methods, and companies developing dMMR drugs below.
Search dMMR Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting dMMR
| Drug | Company | Therapeutic Area |
|---|---|---|
| KEYTRUDA | Merck | Oncology |
| OPDIVO | Bristol-Myers Squibb | Oncology |
| OPDIVO QVANTIG | Bristol-Myers Squibb | Oncology |
| YERVOY | Bristol-Myers Squibb | Oncology |
dMMR Indications
Renal Cell Carcinoma Melanoma Non-Small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Urothelial Carcinoma Colorectal Cancer Hepatocellular Carcinoma Esophageal Cancer Gastroesophageal Junction Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Esophageal Adenocarcinoma Malignant Pleural Mesothelioma Classical Hodgkin Lymphoma Cutaneous Melanoma Microsatellite Instability-High Cancer Mismatch Repair Deficient Cancer Head and Neck Squamous Cell Cancer Primary Mediastinal Large B-Cell Lymphoma Urothelial Cancer Gastroesophageal Junction Adenocarcinoma Cervical Cancer Biliary Tract Cancer Merkel Cell Carcinoma Endometrial Carcinoma Tumor Mutational Burden-High Cancer Cutaneous Squamous Cell Carcinoma Triple-Negative Breast Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer